United Therapeutics (UTHR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tiago Fauth from Wells Fargo maintained a Buy rating on the stock and has a $395.00 price target.
Tiago Fauth has given his Buy rating due to a combination of factors surrounding United Therapeutics’ potential in treating idiopathic pulmonary fibrosis (IPF). The company is heavily reliant on the success of its Tyvaso product, which could significantly impact its growth trajectory over the next decade. The upcoming TETON 2 readout is pivotal, as it could confirm the efficacy of Tyvaso in treating IPF, a condition that is becoming central to United Therapeutics’ strategic focus.
Despite some uncertainties and mixed opinions from key opinion leaders, the current market valuation of United Therapeutics appears to undervalue the potential success of its IPF program. Even with a 50% probability of success, the upside potential is considered transformational, making the risk-reward profile attractive. Fauth believes that the current share price does not fully reflect the value of the IPF program, thus justifying a Buy rating.
Fauth covers the Healthcare sector, focusing on stocks such as Verona Pharma, Amicus, and Insmed. According to TipRanks, Fauth has an average return of -1.6% and a 40.49% success rate on recommended stocks.
In another report released on March 14, J.P. Morgan also maintained a Buy rating on the stock with a $357.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com